[1]杨启明,魏先森.诺欣妥、倍他乐克联合拜新同治疗老年高血压合并慢性心功能不全的临床研究[J].医学信息,2024,37(07):115-119.[doi:10.3969/j.issn.1006-1959.2024.07.022]
　YANG Qi-ming,WEI Xian-sen.A Clinical Study on the Treatment of Senile Hypertension Complicated with Chronic Cardiac Insufficiency by Ningroxinto, Betaloc Combined with Nifedipine[J].Journal of Medical Information,2024,37(07):115-119.[doi:10.3969/j.issn.1006-1959.2024.07.022]
点击复制

诺欣妥、倍他乐克联合拜新同治疗老年高血压合并慢性心功能不全的临床研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年07期
页码:
115-119
栏目:
论著
出版日期:
2024-04-01

文章信息/Info

Title:
A Clinical Study on the Treatment of Senile Hypertension Complicated with Chronic Cardiac Insufficiency by Ningroxinto, Betaloc Combined with Nifedipine
文章编号:
1006-1959（2024）07-0115-05
作者:
杨启明; 魏先森
（1.北京市社会福利医院内科，北京 100085；2.中日友好医院肾内科，北京 100029）
Author(s):
YANG Qi-ming; WEI Xian-sen
(1.Department of Internal Medicine,Beijing Social Welfare Hospital,Beijing 100085,China;2.Department of Nephrology,Beijing Sino-Japanese Friendship Hospital,Beijing 100029,China)
关键词:
高血压; 慢性心功能不全; 老年患者; 诺欣妥; 厄贝沙坦; 倍他乐克; 拜新同
Keywords:
Hypertension; Chronic cardiac insufficiency; Elderly patients; Nuoxintuo; Irbesartan; Betaloc; Nifedipine
分类号:
R544.11；R541
DOI:
10.3969/j.issn.1006-1959.2024.07.022
文献标志码:
A
摘要:
目的 分析诺欣妥、厄贝沙坦分别联合倍他乐克和拜新同治疗，对高血压合并慢性心功能不全老年患者右心房结构与功能的影响。方法 选择本院2021年10月-2022年10月收治的高血压合并慢性心功能不全老年患者180例，按照随机数字表法分为诺欣妥组（给予诺欣妥、倍他乐克、拜新同治疗）与厄贝沙坦组（给予厄贝沙坦、倍他乐克、拜新同治疗），各组90例。比较两组临床疗效及用药安全性，治疗前后血压水平、NT-proBNP水平、心功能（LVEF、TAPSE、右心室侧壁收缩期位移速度、PASP）、右心房结构（RAVlt、RAVIa、RAVIp、RAVpEF、RAVaEF、RAVtEF）变化。结果 诺欣妥组治疗显效率（81.11%）高于厄贝沙坦组（66.67%）（P＜0.05）；但两组总有效率比较，差异无统计学意义（P＞0.05）；诺欣妥组治疗后SBP、DBP高于厄贝沙坦组，NT-proBNP低于厄贝沙坦组（P＜0.05）；诺欣妥组治疗后LVEF、TAPSE、右心室侧壁收缩期位移速度、PASP高于厄贝沙坦组（P＜0.05）；诺欣妥组治疗后RAVlt、RAVIa、RAVIp低于厄贝沙坦组，RAVpEF、RAVaEF、RAVtEF高于厄贝沙坦组（P＜0.05）；两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 诺欣妥、厄贝沙坦分别联合倍他乐克、拜新同均可有效治疗高血压合并慢性心功能不全，且安全性高，但诺欣妥更利于改善左心房结构与功能，提高心功能。
Abstract:
Objective To analyze the effects of norfloxacin and irbesartan combined with betaloc and nifedipine respectively on the structure and function of right atrium in elderly patients with hypertension and chronic cardiac insufficiency.Methods A total of 180 elderly patients with hypertension and chronic heart failure admitted to our hospital from October 2021 to October 2022 were selected. According to the random number table method, they were divided into the noxintuo group (treated with noxintuo, betaloc and bayintong) and the irbesartan group (treated with irbesartan, betaloc and bayintong), with 90 patients in each group. The clinical efficacy and drug safety of the two groups were compared. The changes of blood pressure level, NT-proBNP level, cardiac function (LVEF, TAPSE, right ventricular lateral wall systolic displacement velocity, PASP) and right atrial structure (RAVlt, RAVIa, RAVIp, RAVpEF, RAVaEF, RAVtEF) before and after treatment were compared between the two groups.Results The significant effective rate of nuoxintuo group (81.11%) was higher than that of irbesartan group (66.67%) (P<0.05). However, there was no significant difference in the total effective rate between the two groups (P>0.05). After treatment, the SBP and DBP values of the nuoxintuo group were higher than those of the irbesartan group, and the NT-proBNP value was lower than that of the irbesartan group (P<0.05). After treatment, the systolic displacement velocities of LVEF, TAPSE and right ventricular wall, PSAP in the nuoxintuo group were higher than that in the irbesartan group(P<0.05). After treatment, the levels of RAVlt, RAVIa, and RAVIp in the nuoxintuo group were lower than those in the irbesartan group, while the levels of RAVpEF, RAVaEF, and RAVtEF in the nuoxintuo group were higher than those in the irbesartan group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during the treatment (P>0.05). Conclusion Nuoxintuo and irbesartan combined with betaloc and nifedipine respectively can effectively treat hypertension combined with chronic cardiac insufficiency, with high safety. However, norgestimate is more conducive to improving the left atrial structure and function, as well as cardiac function.

参考文献/References:

[1]赵金艳,崔少楠,曹月娟.沙库巴曲缬沙坦钠治疗老年高血压慢性心力衰竭的疗效观察[J].中华老年心脑血管病杂志,2021,23(12):1268-1271.[2]赵红利,耿锋.厄贝沙坦治疗高血压伴心力衰竭的疗效及其对血清hs-CRP和BNP水平的影响[J].贵州医药,2021,45(1):33-34.[3]彭燕飞,宋初平.倍他乐克缓释片较倍他乐克平片对慢性充血性心力衰竭治疗优势[J].湖南师范大学学报(医学版),2020,17(2):106-109.[4]马博聪,赵明,刘晓雨,等.硝苯地平控释片清晨,夜晚服用对老年高血压患者的疗效及对血管内皮功能的影响[J].岭南心血管病杂志,2020,26(3):337-341.[5]中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.[6]中国老年医学学会高血压分会,国家老年疾病临床医学研究中心中国老年心血管病防治联盟.中国老年高血压管理指南2019[J].中华老年病研究电子杂志,2019,6(2):1-27.[7]向长铁,刘佳丽,张爱民,等.沙库巴曲缬沙坦钠片通过NF2/Mst1信号通路抑制细胞凋亡改善心肌梗死大鼠心肌纤维化[J].中国老年学杂志,2022,42(8):1927-1931.[8]Aimo A,Pateras K,Stamatelopoulos K,et al.Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis[J].Cardiovasc Drugs Ther,2021,35(5):1067-1076.[9]Jackson AM,Jhund PS,Anand IS,et al.Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction[J].Eur Heart J,2021,42(36):3741-3752.[10]Mann DL,Greene SJ,Givertz MM,et al.Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial[J].JACC Heart Fail,2020,8(10):789-799.[11]Mann DL,Givertz MM,Vader JM,et al.Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial[J].JAMA Cardiol,2022,7(1):17-25.[12]Pontremoli R,Borghi C,Perrone Filardi P.Renal protection in chronic heart failure: focus on sacubitril/valsartan[J].Eur Heart J Cardiovasc Pharmacother,2021,7(5):445-452.[13]Zhang J,Yang L,Ding Y.Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy[J].BMC Cardiovasc Disord,2021,21(1):194.[14]Huang C,Huang Y,Zhong Q,et al.Prevalence of and risk factors for abnormal left ventricular geometrical patterns in hypertensive subjects administered irbesartan[J].J Clin Lab Anal,2021,35(3):e23688.[15]Wang GM,Li LJ,Tang WL,et al.Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension[J].Cochrane Database Syst Rev,2020,10(10):CD012569.[16]Dybro AM,Rasmussen TB,Nielsen RR,et al.Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy[J].J Am Coll Cardiol,2021,78(25):2505-2517.[17]Liu C,Yao L,Zhang L,et al.Effect of metoprolol tartrate tablets and recombinant human B-type natriuretic peptide on the sudden cardiac death and malignant arrhythmias in patients with acute myocardial infarction and heart failure[J].Pak J Pharm Sci,2021,34(6):2473-2478.[18]Heusch G,Kleinbongard P.Is metoprolol more cardioprotective than other beta-blockers?[J].Eur Heart J,2020,41(46):4441-4443.[19]Qin W,Zhang L,Li Z,et al.Metoprolol protects against myocardial infarction by inhibiting miR-1 expression in rats[J].J Pharm Pharmacol,2020,72(1):76-83.[20]Li Q,Huang K,Ma T,et al.Metoprolol Protects Against Arginine Vasopressin-Induced Cellular Senescence in H9C2 Cardiomyocytes by Regulating the Sirt1/p53/p21 Axis[J].Cardiovasc Toxicol,2022,22(2):99-107.

相似文献/References:

[1]颜 明,龚丽娜,王淑清.彩超在高血压患者肾动脉血流动力学检测中的应用分析[J].医学信息,2018,31(02):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
　YAN Ming,GONG Li-na,WANG Shu-qing.Application of Color Doppler Ultrasound in the Measurement of Renal Artery Hemodynamics in Patients with Hypertension[J].Journal of Medical Information,2018,31(07):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
[2]夏能能,任 薇,杜建平,等.1953~2016年中医药治疗高血压领域研究热点分析[J].医学信息,2018,31(04):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
　XIA Neng-neng,REN Wei,DU Jian-ping,et al.Analysis of Hot Spots in the Research of Traditional Chinese Medicine in Treating Hypertension from 1953 to 2016[J].Journal of Medical Information,2018,31(07):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(07):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(07):65.[doi:10.3969/j.issn.1006-1959.2018.07.021]
[5]董巧玲.健康教育对原发性高血压患者治疗效果的影响[J].医学信息,2018,31(09):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
　DONG Qiao-ling.Effect of Health Education on Treatment of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(07):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
[6]沈 正,王庆海.焦虑抑郁障碍与血压变异性研究[J].医学信息,2018,31(16):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
　SHEN Zheng,WANG Qing-hai.Study on Anxiety and Depression Disorder and Blood Pressure Variability[J].Journal of Medical Information,2018,31(07):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
[7]左洪亮.苯磺酸左旋氨氯地平片治疗中老年患者 轻中度原发性高血压的疗效观察[J].医学信息,2018,31(16):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
　ZUO Hong-liang.Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients[J].Journal of Medical Information,2018,31(07):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
[8]袁 敏,周袁成.钙离子拮抗剂类降压药的临床应用与不良反应分析[J].医学信息,2018,31(17):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
　YUAN Min,ZHOU Yuan-cheng.Clinical Application and Adverse Reaction Analysis of Calcium Antagonist Antihypertensive Drugs[J].Journal of Medical Information,2018,31(07):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
[9]陈学军,李 敏,张 丹,等.社区一体化分级管理模式对社区老年高血压患者的管理效果[J].医学信息,2018,31(18):169.[doi:10.3969/j.issn.1006-1959.2018.18.055]
　CHEN Xue-jun,LI Min,ZHANG Dan,et al.Management Effect of Community Integration Hierarchical Management Mode on Elderly Hypertensive Patients in Community[J].Journal of Medical Information,2018,31(07):169.[doi:10.3969/j.issn.1006-1959.2018.18.055]
[10]张莉莉.左旋氨氯地平和氨氯地平治疗轻中度高血压临床效果观察[J].医学信息,2018,31(21):149.[doi:10.3969/j.issn.1006-1959.2018.21.043]
　ZHANG Li-li.Clinical Efficacy of Levamlodipine and Amlodipine in Treatment of Mild to Moderate Hypertension[J].Journal of Medical Information,2018,31(07):149.[doi:10.3969/j.issn.1006-1959.2018.21.043]

更新日期/Last Update: 1900-01-01